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Abstract
Background: Infantile spasms (IS) is a specific type of epileptic encephalopathy associated with severe developmental
disabilities. Genetic factors are strongly implicated in IS, however, the exact genetic defects remain unknown in the
majority of cases. Rare mutations in a single gene or in copy number variants (CNVs) have been implicated in IS of
children in Western countries. The objective of this study was to dissect the role of copy number variations in Chinese
children with infantile spasms.
Methods: We used the Agilent Human Genome CGH microarray 180 K for genome-wide detection of CNVs. Real-time
qPCR was used to validate the CNVs. We performed genomic and medical annotations for individual CNVs to
determine the pathogenicity of CNVs related to IS.
Results: We report herein the first genome-wide CNV analysis in children with IS, detecting a total of 14 CNVs in a
cohort of 47 Chinese children with IS. Four CNVs (4/47=8.5%) (1q21.1 gain; 1q44, 2q31.1, and 17p13 loss) are
considered to be pathogenic. The CNV loss at 17p13.3 contains PAFAH1B1 (LIS1), a causative gene for lissencephaly.
Although the CNVs at 1q21.1, 1q44, and 2q23.1 have been previously implicated in a wide spectrum of clinical
features including autism spectrum disorders (ASD) and generalized seizure, our study is the first report identifying
them in individuals with a primary diagnosis of IS. The CNV loss in the 1q44 region contains HNRNPU, a strong
candidate gene recently suggested in IS by the whole exome sequencing of children with IS. The CNV loss at 2q23.1
includes MBD5, a methyl-DNA binding protein that is a causative gene of ASD and a candidate gene for epileptic
encephalopathy. We also report a distinct clinical presentation of IS, microcephaly, intellectual disability, and absent
hallux in a case with the 2q23.1 deletion.
Conclusion: Our findings strongly support the role of CNVs in infantile spasms and expand the clinical spectrum
associate with 2q23.1 deletion. In particular, our study implicates the HNRNPU and MBD5 genes in Chinese children
with IS. Our study also supports that the molecular mechanisms of infantile spasms appear conserved among different
ethnic backgrounds.
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Infantile spasms(IS; also known as West syndrome) is a
severe and specific type of epilepsy syndromes or epilep-
tic encephalopathies that presents in early infancy. IS is
characterized by the early onset (4–8 months of age) of
the epileptic form of spasm, a distinct hypsarrhythmia
on EEG, and poor developmental outcome [1]. The inci-
dence of IS ranges from 0.25 to 0.4 per 1000 living births
in Western countries. The prevalence of IS in Chinese
children is not known but is estimated to be similar to
that observed in the Caucasian population. Due to its re-
fractory nature to most antiepileptic treatments and its
frequent association with poor cognitive development,
IS is one of the most devastating epileptic encephalop-
athies and neurological disorders of infancy and early
childhood. Interestingly, IS has been shown to be
strongly associated with autism spectrum disorders
(ASD) [2]. Infantile spasms is a prominent clinical fea-
ture in several high profile monogenic syndromes such
as tuberous sclerosis complex (TSC). Mutations in a
growing number of genes have also been reported in in-
dividuals with nonsyndromic infantile spasms by med-
ical re-sequencing or whole exome sequencing projects
[3-5]. These genes include ARX, CDKL5, FOXG1,
GRIN1, GRIN2A, MAGI2, MEF2C, SLC25A22, SPTAN1,
CACNA1A, CHD2, FLNA, NEEDL4,a n dSTXBP1.D e s -
pite these findings, the causes for the majority of infant-
ile spasms cases remain unknown. Recently, rare and
recurrent genomic copy number variants (CNVs) have
been implicated in intellectual disabilities, ASD, and
other neuropsychiatric disorders. Many of these same
CNVs have also been implicated in individuals with
generalized epilepsy in Caucasian population [6-11].
However, the role of CNVs in IS has not been fully in-
vestigated. The clinical presentations of IS in Chinese
children remain poorly characterized. There are few
published reports on genomic or genetics studies of IS
in Chinese children. We hypothesized that CNVs also
contribute significantly to the susceptibility of IS in
Chinese children. We conducted the first genome-wide
copy number variation analysis in 47 Chinese children with
IS using an array comparative genomic hybridization (array
CGH) technique. We detected a total of 364 CNVs by
array-CGH and validated 14 rare, inherited or de novo
CNVs by further molecular experiments in this cohort.
Genomic and medical annotations provided evidence that
support the pathogenicity of several new CNVs, specifically,
those in the HNRNPU and MBD5 genes, in IS.
Methods
Study subjects
The study was approved by the institutional review board
(IRB) of the Children′s Hospital of Fudan University. All
the photographs of the children with or without eyes
blocked have consent from their parents. All samples and
information were collected after informed consent was ob-
tained from the parents. The diagnosis of infantile spasms
was made based on an assessment of clinical seizure pres-
entation and electroencephalography (EEG) recorded by a
pediatric neurologist with experience in the clinical diag-
nosis of infantile spasms (Additional file 1: Table S1). All
patients included in this study had cranial magnetic reson-
ance imaging (MRI), G-band karyotype and basic meta-
bolic screening tests. The detailed medical findings and
family history were also obtained. All patients with a
documented history of infection in the central nervous
system, a significant history of hypoglycemia, hypoxic
ischemic encephalopathy, extreme premature birth, or
other documented non-genetic insults were excluded.
In addition, any cases with a clinical diagnosis of neuro-
cutaneous syndromes such as tuberous sclerosis complex
or other known genetic syndromes were not enrolled in
this study.
Comparative genomic hybridization or microarray analysis
The array CGH was performed using an Agilent Human
Genome CGH microarray 180 K kit (Agilent Technolo-
gies Inc. Shanghai, China) with a resolution of 6.4 kb.
For each sample, 1.5 μg of genomic DNA was used for
each array CGH experiment. The array CGH experi-
ments were performed according to the manufacturer’s
instruction as described previously [12]. Briefly, genomic
DNA from patients and controls was digested with the
restriction enzymes AluI and RsaI (Promega) and fluo-
rescently labeled with Cy5 (patients) or Cy3 (controls)
using the Agilent DNA Labeling Kit. Labeled DNAs
were combined, denatured, pre-annealed with Cot- DNA
(Invitrogen) and blocking reagent (Agilent), and then
hybridized to the arrays for 40 hours in a rotating oven
(Agilent Technologies) at 65°C and a speed of 20 rpm.
After performing the hybridization step and the recom-
mended washes, the arrays were scanned at 5 μm reso-
lution with an Agilent G2505A scanner. The images
were analyzed using the Feature Extraction software
(Agilent Technologies, Shanghai, China). All array data
that passed the quality metrics were further processed
by the DNA Analytics software.
Array CGH data analysis and CNV calling
Array CGH data were analyzed using the Cytogenomics
v2.5 software (Agilent Technologies, CA,USA). The QC
metrics table was used to check the signal intensities and
background noise. A DLR (Derivative Log Ratio) score
above 0.20 was set as the cutoff criteria and those with
below DLR 0.20 score indicate poor quality of array data
and possibility of false CNV calling. CNV calls were per-
formed using the ADM2 algorithm with a sensitivity
threshold of 6.0 and a minimum of 5 probes. The non-
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including Database of Genomic Variants (DGV) and pub-
lished CNV dataset from Chinese Han individuals.
Validation of CNVs by quantitative real-time PCR (qPCR)
For each CNV identified in this study, we confirmed the
CNV gain or loss using quantitative PCR (qPCR) in pro-
bands and their parents. The primers used for qPCR were
derived from the candidate genes within the CNVs that
were also related to genetic disease in the OMIM database.
Three to five primer pairs for each gene were selected for
quantitative PCR (qPCR). The sequence of these primer
pairs are listed in Additional file 1: Table S2. PCR reactions
were performed in a volume of 10 μl containing 5 μlS Y B R
Green I Master mix (Toyota, China), 0.4 mM primers, and
approximately 25 ng template cDNA. The housekeeping
gene HMBS was used as an endogenous control for
normalization. The reactions for each sample were per-
formed in triplicate using a StepOnePlus™ Real-Time PCR
System (Applied Biosystems®). The thermal profile for the
qPCR was as follows: a pre-incubation step of 45 sec at 95°
C, followed by 40 cycles of 5 sec at 95°C, 30 sec at 60°C,
and 30 sec at 72°C. The raw data were analyzed using Ste-
pOne™ Software v2.1. Amplification levels were calculated
using the ΔΔCt method according to the manufacturer’s
instructions.
Sequence analysis of MBD5 and ORC4
Primers flanking the MBD5 (NM_018328) and ORC4
(NC_000002) exon-intron junctions were designed to
amplify the exons of these two genes using the Primer 3
online program. The sequences of these primers are listed
in the Additional file 1: Table S3. Touchdown PCR was
performed for all of the other amplicons. Briefly, cycling
conditions comprised 10 cycles of: 30 sec denaturation at
95°C, 30 sec annealing and 72°C, 40 sec for primer exten-
sion. The annealing temperature was decreased 0.5°C
every second cycle from 63°C to 58°C, followed by 25 add-
itional cycles with an annealing temperature of 58°C. The
direct sequencing of PCR products was carried out using
an ABI Prism Big Dye System (Applied Biosystems). The
raw sequencing data were processed, and variant calling
was performed using the Mutation Surveyor v3.97 soft-
ware program (SoftGenetics, PA, USA).
Statistical analysis
Data were analyzed using SPSS (Statistical Package for the
Social Sciences) version 18.0 statistical software (SPSS
Inc., Chicago, IL). A one-way ANOVA test followed by
LSD was used when comparing three groups. A p value of
p<0.05 (two-tailed) was considered significant.
Results
Study subjects
A total of 47 patients (24 males and 23 females) with a clin-
ical diagnosis of IS were enrolled in this study (Additional
file 1: Table S1). The diagnosis of IS was supported by both
a characteristic clinical presentation of seizures and an ab-
normal EEG with hypsarrhythmia that is unique to IS in 45
patients. Two patients exhibited clinical presentations of
infantile spasms without a typical EEG pattern of hypsar-
rhythmia in the recording at the time of enrollment (aged
8 months-old and 13 months-old). The mean age of sub-
jects at enrollment was 20.2±19.7 months. The average
onset of infantile spasms was 6.3±2.9 months.
All patients displayed developmental delay and intel-
lectual disability. Brain structural MRI analyses were
performed for all participants. Abnormalities including
pachygyria, corpus callosum dysplasia, enlarged CSF space,
diffuse and abnormal cortical migration, and atrophy were
found in 5 patients (Additional file 1: Table S1). Other
congenital anomalies, including heart defects and limb
anomalies, were found in 7 out of 47 cases. The parents of
all the probands were reported to be healthy and did not
have history of seizure disorders. One family (S133) had
two affected boys (2 and 8 years-old) with IS, motor devel-
opment delay, speech and cognitive impairment.
Genome-wide copy number variation analysis
G-band karyotyping and routine clinical biochemical
screening tests for inborn errors of metabolism were per-
formed in all participants to rule out common known gen-
etic and metabolic conditions. No specific abnormalities
were identified in these tests. An array CGH analysis was
performed for all probands using an Agilent Human Gen-
ome CGH microarray 180 K array. The CNV calling and
filtering were described previously [12]. A Han Chinese
specific CNV dataset obtained from multiple sources was
used for the CNV analyses [13-15]. The CNVs called by
the computational program were validated primarily by
real-time quantitative PCR (qPCR) analyses. A total of 364
CNVs were identified from 47 individuals (7.7 CNVs/per
case). After filtering and annotation, 14 CNVs (5 deletions
and 9 duplications) were further validated by molecular
experiment by the real time qPCR using the primers
within the genes mapped to the deleted or duplicated in-
tervals (Additional file 1: Table S2). The sizes of the CNVs
ranged from 115 kb to 4.1 Mb. One proband (S34) had
two CNVs while the rest of the cases had a single CNV.
Parental testing was performed on both parents for 12
CNVs. Six CNVs were de novo and 6 were either mater-
nally or paternally inherited. In other two families (S2 and
S75), parental test was not performed because either one
or both parents were not available for testing.
We conducted genomic and medical annotations for
each CNV that were identified and confirmed from this
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viewing the function of the candidate genes residing
within the deleted or duplicated interval of the CNVs
and absence in the DGV. The medical annotation was
performed by reviewing the clinical reports related to
each of the CNVs in PubMed, the candidate gene(s) in
CNVs relevant to the OMIM entries, and the function of
these genes in the evidence provided by other model or-
ganisms or experimental systems. Through these ana-
lyses, we determined the pathogenicity of the CNVs in
IS based on a comprehensive assessment of the existing
clinical data, the size of the CNV, the gene content of
the CNV, and the inheritance of the CNV. These CNVs
were placed into 3 classes based on the evidence sup-
porting their pathogenicity in IS: 1) pathogenic; 3) un-
known clinical significance; and 3) probably benign
(Table 1). The molecular and clinical characteristics of
each class of CNVs are discussed below.
Pathogenic CNVs
Four CNVs were classified as pathogenic (Table 1). In
case S100, a de novo 115-kb deletion was detected in
the 17p13.3 region (chr17:2,405,454-2,520,464, www.
genome.ucsc.edu; hg19, thereafter) in a boy diagnosed
with IS (Figure 1A and D). The proximal breakpoint of
t h ed e l e t i o ni sw i t h i ni n t r o n2o fMETTL16,ag e n et h a t
encodes a methyltransferase-like protein. But the exact
function of this protein has not been determined bio-
chemically. The distal breakpoint was within an intron 1
of PAFAH1B1 (LIS1), a gene known to cause lissencephaly
and the feature of IS [16]. This patient developed IS at
4 months of age and the diagnosis of IS was supported by
an EEG pattern of hypsarrhythmia. The patient had mild
dysmorphic facial features including hypertelorism and
micrognathia (Figure 1B). Structural brain MRI analysis
revealed diffuse and generalized pachygyria and grade III
to IV lissencephaly (Figure 1C) that is consistent with the
clinical findings in other patients with similar defects of
PAFAH1B1. Generalized seizures and infantile spasms are
common clinical features associated with deficiency of
PAFAH1B1 [16,17].
In case S37, a de novo 2.1-Mb deletion was found in the
1q44 region (chr1:244,961,797–247,074,490) in a boy with
a primary diagnosis of IS (Figure 2A and D). The patient
developed IS at 5 months of age and the EEG indicated
hypsarrhythmia and epileptiform of activity. Physically,
he had a prominent forehead and small chin (Figure 2B).
Structural brain MRI analysis showed delayed myelination
and some degree of cortical dysplasia (Figure 2C). There
was a history of developmental regression after the onset of
IS. At 2 years of age, his language development was severely
delayed. His behavioral profile was consistent with a clinical
diagnosis of ASD. The deleted region contains 8 known
genes including COX20, HNRNPU, EFCAB2, SMYD3,
TFB2M, CNST, SCCPDH,a n dAHCTF1 (Figure 2A).
Interestingly, a sequence variant at the splice acceptor site
of HNRNPU was found in a patient with infantile spasms
by whole exome sequencing (WES) in Epi4K project
Table 1 Rare and novel CNVs identified from Chinese infantile spasms children
Subject Sex Onset of IS
(month)
EEG
(HYPS+/−)
Genomic location/coordinates
(hg19)
Genomic
event
Size Inheritance Candidate
gene(s)
Pathogenic
S100 M 4 + chr17:2,405,454-2,520,464 Del 115 Kb De novo PAFAH1B1
S37 M 5 + chr1:244,961,797-247,074,490 Del 2.1 Mb De novo HNRNPU
S162 F 6 - chr2:147,953,313-152,061,251 Del 4.1 Mb De novo MBD5
S67 F 10 + chr1:145,764,453-147,824,207 Dup 2.0 Mb De novo CHD1L
Unknown clinical significance
S15 F 2 + chr10:84,222,075-85,293,140 Dup 1.0 Mb Paternal NRG3
S34 M 5 + chrX:102,262,951-102,659,333 Dup 396 kb Maternal NGFRAP1
S134 F 4 + chr17:14,111,754-15,442,119 Del 1.3 Mb Paternal PMP22
S163 F 4 + chrX:6,451,691-8,115,193 Dup 1.6 Mb Paternal STS,VCX3A
S165 M 5 + chr11:101,857,720-102,256,635 Del 398 kb De novo YAP1
Probably benign
S2 M 3 + chr2:216,898,976-217,160,487 Dup 261 kb Not determined
S34 M 5 + chr2:137,826,656-138,048,583 Dup 221 kb Paternal
S42 M 4 + chr4:48,983,002-49,063,489 Dup 80 kb Paternal
S75 M 6 + chr6:118,989,529-120,238,639 Dup 1.2 Mb Not determined
S133 M 13 - chr8:135,644,952-135,791,363 Dup 146 Kb De novo
Du et al. BMC Medical Genetics 2014, 15:62 Page 4 of 12
http://www.biomedcentral.com/1471-2350/15/62[14,18]. Our findings thus provide further support that
HNRNPU in the 1q44 region is pathogenic or causative
gene for infantile spasms in this case.
We also detected a deletion in the 2q23.1 region in-
cluding MBD5 gene in case S162 (Table 1 and Figure 3A)
and a duplication in the 1q21.1 region in case S67 (data
not shown), respectively. The CNVs in these two regions
have previously been implicated in a wide spectrum of
clinical presentations that include ASD, intellectual
disability and seizure, but not specifically IS [19-21]. In
case S162, a 4.1-Mb deletion in the 2q23.1 region was
found in a 7 month-old female (Figure 3A and B). The
size of the deletion was moderate compared to other
cases in the literature that ranged from 100 kb to 6 MB
in the region [20]. The seizures in proband started at
4 days of age and then transformed into spasms at
6 months of age. An EEG study indicated the presence
of a bilateral sharp wave and spike slow wave complex at
Figure 1 A patient (S100) with a 115-kb microdeletion at 17p13.3 that disrupts the PAFAH1B1 (LIS1) gene. A) A local view of the 17p13.3
deletion. The proximal breakpoint is within intron 2 of METTL16, a gene that encodes methyltransferase-like 16 protein whose exact function has
not been characterized. The distal breakpoint is within intron 1 of PAFAH1B1 (LIS1), a known causative gene for lissencephaly. The black arrows are
the direction of transcription. B) The clinical features of a patient with a prominent forehead and micrognathia. C) Structural MRI analysis showed
grade III lissencephaly. D) Analyses by qPCR confirmed that the copy number loss in this patient was de novo using three different primers
(P1-P3) within the PAFAH1B1 and analyses of both parents. *p< 0.01, proband vs parents and control.
Figure 2 The proband of S37 with a 2.1-Mb microdeletion at 1q44 that disrupts the infantile spasms candidate gene HNRNPU reported
by the WES study. A) A local view of the 1q44 deletion and genes in the deleted interval. The black arrows are the direction of transcription of
genes. B) The clinical features of a proband with a dysmorphic face. C) Structural MRI analysis showed delayed myelination in the brain. D) qPCR
confirmed the copy number loss in probands using three different primers (P1-P3) within HNRNPU. *p< 0.01, proband vs parents and control.
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Structural brain MRI analysis showed some degree of
cortical dysplasia and microcephaly. She also had dys-
morphic face including a broad forehead, arched eye-
brows, and deep nasal bridge (Figure 3C). Her great toes
were bilaterally absent (absent hallux) and the fifth fin-
gers were short and exhibited clinodactyly (Figure 3D).
An X-ray study revealed missing proximal and distal
phalanges in the great toes but normal knee joints. She
also had significant hypotonia, severe language delay,
and suspected ASD diagnosis.
The 2q23.1 deletion has been reported in individuals
with ASD, seizure, and developmental delay. However, the
overall neurological presentations in our case appeared
much more severe than in other individuals with similar
sized deletions in 2q23.1 in three other major reports con-
sidering the degrees of hypotonia and the onset of seizures
[20,22-24] (Table 2). Although the mild anomalies of hand
and foot has been seen in most patients with MBD5 defect,
the features of IS and the absent hallux limb anomaly
have not been reported previously. We then tested the
hypothesis that the sequence variants for the genes in
the deleted interval of the non-deleted chromosome
m a ym o d i f yo rc o n t r i b u t et om o r es e v e r ea n du n i q u e
clinical presentations in this case. There are a total of 8
genes within the deleted intervals (chr2:147,953,313-
152,061,251) in our case (Figure 3A), including three
classified as known disease-causing genes listed in the
OMIM: MBD5, ORC4,a n dMMADHC. MBD5 is an im-
portant gene within the 2q23.1 region that was believed
to be responsible for ASD, intellectual disabilities, devel-
opmental delays and seizures in 2q23.1 deletion because
point mutations in MBD5 shared the key neurological fea-
tures with 2q23.1 deletion (Tab1e 2) [20,22-24]. ORC4 is a
causative gene of a subtype of Meier-Gorlin syndrome
(MGS), a rare autosomal recessive disorder characterized
by severe intrauterine and postnatal growth retardation,
developmental delay, microcephaly, bilateral microtia, and
aplasia or hypoplasia of the patellae. In our case, the X-ray
study did not reveal abnormal patellae. The clinical pre-
sentations are not consistent with the diagnosis of MGS.
The MMADHC gene is responsible for the cobalmin
(cbl)-D type of methylmalonic aciduria. The metabolic
profile in our case did not suggest a defect in cobalmin
metabolism. Because the functions of both MBD5 and
ORC4 are important for brain function, we tested whether
Figure 3 A patient from S162 with a 4.1-Mb microdeletion at 2q23.1 that disrupts the known ASD causative gene MBD5.A )A local
view of the 4.1 Mb 2q31.1 deletion and genes in the deleted interval. B) Analysis by qPCR confirmed the copy number loss and de novo event in
the patient using 7 primers (MBD5E6-E13) from exons 5–13 of MBD5. C) The clinical features of a proband with a dysmorphic face, including a
coarse face. D) Clinodactyly of the fifth finger, excessive fat pads of the second and middle fingers, and the absence of great toes. E) X-ray
analyses showed the absence of the distal and proximal phalanges of the great toes. *p <0.01, proband vs parents and control.
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allele were present in this patient. We sequenced the cod-
ing exons of MBD5 and ORC4. The primers used for
sequencing and PCR are included in Additional file 1:
Table S3. No significant sequence variants were identified
in all coding exons of MBD5 and ORC4 genes.
In case S67, a de novo 2 Mb duplication at 1q21.1
(chr1:145,764,453- 147,824,207) was found in a 4-year-
old girl with a diagnosis of IS. The duplication spanned
the 1q21.1 distal region but did not include the TAR
(thrombocytopenia with absent radius) syndrome region.
The size of this duplication is larger than many of the
cases described by Brunetti et al. [25] and Mefford et al.
[26] but is similar to other recently reported cases [27].
The probe coverage may contribute to the discrepancy
for the estimated size of duplication in different reports.
Duplication at 1q21.1 has been implicated in a wide
spectrum clinical presentations including ASD, congenital
heart defects, seizures, schizophrenia, and developmental
delay [25-27]. In our case, the proband developed IS at
8 months of age with EEG of hypsarrhythmia epileptiform
activity. The spasms were poorly controlled and progressed
Table 2 Comparison of clinical features of 2q23.1 deletion in this study and other cohorts or MBD5 specific mutation
Clinical Features MBD5-specific mutation
20,22–24 2q23.1 Deletion
20,22–24 Case in this study
Number Percentage Number Percentage +, present; − absent
Neurological
Development delay 20/21 95% 53/55 96% +
Language impairment 12/21 57% 38/55 69% +
Seizure 11/21 52% 32/55 58% +
Infantile spasms 0/21 0 0/55 0 +
Infantile hypotonia 4/21 19% 23/55 41% +
Growth/Endocrine
Short stature 5/21 24% 25/55 45% -
Local hirsutism 0/21 0 4/55 7% -
Craniofacial abnormalities
Coarse face 0/21 0 3/55 5% +
Broad forehead 3/21 14% 4/55 7% +
Microcephaly 1/21 5% 26/55 47% +(<2SD)
Synophrys 2/21 9% 10/55 18% +mild
Nasal abnormalities 7/21 33% 35/55 64% +
Open mouth 3/21 14% 23/55 42% +
Downturned corners of the mouth 3/21 14% 17/55 31% +
Macroglossia or protruding tongue 2/21 9% 6/55 11% -
Dental abnormalities 4/21 19% 13/55 24%
Skeletal abnormalities +
Small hands and feet 1/21 5% 23/55 42% +
Clinodactyly, 5th finger 2/21 9% 22/55 40% +
Brachydactyly 0/21 0 13/55 24% +
Short fifth digit of hands/feet 1/21 5% 14/55 25% +
Absent hallux 0/21 0 0/55 0 +
Behaviors -
Autistic feature 13/21 62% 44/55 80% +
Sleep disturbance 5/21 24% 17/55 31% ND
Self-injurious behavior 2/21 9% 17/55 31% +
Other -
Cardiovascular abnormalities 1/21 5% 4/55 7% -
Urogenital abnormalities 1/21 45% 1/55 2% -
ND, not documented.
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brain MRI analysis uncovered mild delayed myelination
and enlarged ventricles. Her cognitive development
regressed significantly after the onset of spasms. There
are more than 20 genes within the 2 Mb duplicated
interval and the knowledge for which gene or genes are
responsible for neurological phenotypes is limited. CHD1L,
a gene encoding chromodomain helicase DNA binding
protein 1-like, was mapped to this interval.
CNVs of unknown clinical significance
Five novel de novo or inherited CNVs were considered to
have potential roles in IS because of their size and the
known function of the gene in the brain. However, the
exact clinical relevance could not be determined with con-
fidence. These CNVs include the following: 1) a paternally
inherited 1.07 Mb duplication in chromosome 10q22.3
that contains NRG3, a gene implicated in schizophrenia
and other neuropsychiatric diseases [28,29], 2) a maternally
inherited 396 kb duplication at Xq22.1 (chrX:102,262,951-
102,659,333) in a boy (S34). The duplication contains
NGFRAP1 (NADE) ,ag e n et h a te n c o d e san e r v eg r o w t h
factor receptor-associated protein. The NGFRAP1 protein
notably interacts with TSC1 [30], a protein responsible for
TSC, a genetic disorder in which infantile spasms is a com-
mon feature; 3) a pateral1y inherited 1.6 Mb duplication at
Xp22.31 in S163 that contains two OMIM genes of STS
and VCX3A (chrX:6,451,691- 8,115,193). The deletion in-
cluding STS and VCX3A was found in two cases with ich-
thyosis and/or mental retardation. The duplication of
Xp22.31 region has been reported but the clinical rele-
vance has not been determined [31,32]. The function of
STS and VCX3A in brain is not known; 4) a paternally
inherited deletion in the 17p12 region that contains
PMP22, a gene that causes a hereditary neuropathy with
liability to pressure palsies (HNPP, OMIM 162500) [33];
and 5) a de novo 398-kb deletion in the 11q22.1 region
in S165 (chr11:101,857,720-102,256,635) that contains a
gene encoding YAP1, a protein that associates with 14-
3-3 in an AKT-dependent manner that is important for
brain function [34].
Although these CNVs are rare and novel, their roles in
the clinical presentation of IS are not immediately clear.
In the case with the CNV gain at 10q23.1, the Neuregulin
3 (NRG3) gene, a family of neurally expressed proteins
that perform a wide range of functions in the developing
nervous system, mapped within this region. The break-
point of duplication was within the middle of NRG3 cod-
ing exons. Therefore, it is not clear what was the impact
of this duplication to the expression of NRG3. There are
numerous reports suggesting that NRG3 contributes to
the susceptibility of schizophrenia and other neuropsychi-
atric disorders [28,35,36]. In our case, because the duplica-
tion is inherited from the healthy parent, the role of this
duplication in proband related to IS could not be deter-
mined with confidence. In the case S34, a 396 kb duplica-
tion in X chromosome containing NGFRAP1(NADE) gene
in boy was inherited from the healthy mother. The similar
duplication has not been reported before associated with
disease in humans. The function of NGFRAP1 related to
TSC1 suggested that the NGFRAP1 may be a risk factor
for the IS. The similar scenario is applied to the case of
S165 with a de novo 398-kb deletion in the 11q22.1 region.
YAP1, a protein important for brain function is mapped to
the region but the similar deletion has not been associated
with disease phenotype in human. In case S134, the father
carrying the same deletion containing PMP22 gene ap-
pears healthy and does not have clinical symptoms, sug-
gesting a diagnosis of PMP22-related HNPP at the age of
30s. It is possible that father may have a late onset of
HNPP. There is no report indicating that seizure or IS is a
feature of individuals with HNPP [33]. Therefore, it is less
likely that PMP22 related CNV found in proband is a risk
factor for IS and additional investigation is warranted to
search for another possible cause in this case.
Probably benign CNVs
Five CNVs in cases of S2, S34, S42, S75, and S133 are
probably benign or non-pathogenic to IS despite their rare
occurrence in the controls. The sizes of these CNVs were
small. There are no functionally significant genes within
these CNVs. The inheritance is either de novo,i n h e r i t e d ,
or unknown. We thus reasoned that these CNVs are more
likely to be benign or very unlikely to contribute to IS.
Discussion
Here, we report the first genome copy number variation
analysis in a cohort of 47 Chinese children with IS. Our
study identified four pathogenic CNVs (17p13.3, 1q44,
2q23.1, and 1q21.1) involving genes of PAFAH1B1(known),
HNRNPU (known), MBD5 (new), and CHD1L (new) in 47
Chinese children with a primary diagnosis of IS. The
17q13.3 deletion containing PAFAH1B1(LIS1) gene is
known to be responsible for IS [16]. The finding of CNVs
at 1q44, 2q23.1, and 1q21.1 in IS is novel and reported for
the first time. The overall positive detection rate for patho-
genic CNV in this cohort was 8.5% (4/47), which is similar
or slightly higher than the rates reported in other studies
of IS [8,37]. The detection rate of epilepsy syndromes
other than infantile spasms or epileptic encephalopathy
varied [9,11]. This difference is most likely related to pa-
tient selection in different studies. As noted, the patients
in our cohort have a higher percentage of congenital
anomalies that may contribute to the higher positive de-
tection rate of CNVs in our study.
The identification of a small 115-kb microdeletion dis-
rupting PAFAH1B1(LIS1) gene is consistent with the clin-
ical presentations of lissencephaly and IS [16]. The CNV at
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seizures, brain malformation, and developmental delay
[38,39]. However, an association of this CNV with IS has
not been reported previously. More importantly, a se-
quence in the splice acceptor site of HNRNPU in individ-
ual with IS was recently reported by WES in epi4K project
[4]. Together, these results indicate a pathogenic role of
the 1q44 deletion, and primarily, HNRNPU deficiency in
IS. The CNVs at 1q21.1 and 2q23.1 have been previously
implicated in a wide spectrum of clinical presentations in-
cluding intellectual disabilities, congenital anomalies, ASD,
and generalized seizures but not in IS [19,20]. These may
simply be due to the clinical information in these reports
were typically extracted from limited medical records for
the subjects in the studies. In other cases, the features
of IS may be age dependent and missed at time of re-
cruitment. Our findings then support a careful review of
clinical records or re-evaluation clinically to determine
whether IS is more prevalent in 2q23.1 deletion cases.
The MBD5 gene within the 2q23.1 deletion has been
s h o w nt ob et h ep r i m a r yg e n er e s p o n s i b l ef o rn e u r o -
logical features of ASD, seizures, and intellectual dis-
ability [20,22,23]. Recently, a deleterious mutation in
MBD5 was found in a patient with epileptic encephal-
opathy [40]. The CHD1L gene in 1q21.1 is interesting
candidate. The known functions of CHD1L in the litera-
ture are primarily related to cancers [26]. However, it
was noted that CHD2, a protein that belongs to the
same family as CHD1L, has been strongly implicated in
epileptic encephalopathy in several recent studies [40,41].
Together with our study, these results support a conclu-
sion that MBD5 and HNRNPU play an important role in
the susceptibility to IS and epileptic encephalopathy. Our
study is the first to report these pathogenic CNV in Chin-
ese children. These findings then suggest that, despite the
different genome architecture of CNVs between Caucasian
and Chinese populations [13-15], the pathogenic CNVs
appear conserved between two populations.
The clinical presentations of our case with a deletion
at 2q23.1 shares similar feature but has distinct and
more severe neurological presentations than other cases
with similar sized deletions [20,22-24] (Table 2). These
may suggest additional genomic variants in genome may
modify clinical phenotypes. The hypotonia appeared to
be more prominent and the onset of seizure was much
earlier than in other cases reported in literature. Inter-
estingly, while mild finger anomalies are common in pa-
tients with 2q23.1 deletions, the absence of the great
toes has not been reported previously. The physical sign of
absence of the great toes is not suggestive of other causes,
such as amniotic band sequence, because the second toes
are apparently larger than expected (Figure 3D). The ab-
sence of the great toes is a rare clinical manifestation in lit-
erature. The interesting question is whether this is an
expanded clinical feature of the 2q23.1 deletion syndrome
or whether it has a different cause other than the 2q23.1
deletion.
The combination of keyword searching using ‘seizure’
and ‘absent great toes’ in the London dysmorphology
database, a comprehensive dysmorphology database for
genetic syndromes, revealed no entries [42]. A search of
PubMed using the key words ‘absent great toes’ revealed
only one case report of hypoplasia of hallux that was as-
sociated with microphthalmia, facial anomalies, micro-
cephaly, thumb hypoplasia, and agammaglobulinemia
[43]. These presentations are clearly different from our
case. It remains to be seen whether the feature of absent
great toes is unique to the Chinese children with MBD5
related 2q23.1 deletions. If this is caused by a different
genetic cause, we speculate that the unique presentation
of microcephaly, infantile spasms, and absent hallux may
define a new genetic syndrome requiring further delinea-
tion in additional cases.
To our knowledge, there are three genome-wide CNV
studies specifically to IS in the literature [7,8,37]. Two
similar studies in Caucasian children reported previously
[8,37]. Another report analyzed CNVs using data from
cases with IS that were referred to a clinical diagnostic
laboratory [7] (Table 3). A large WES study on IS was re-
ported as part of the epi4K project on epileptic encephal-
opathy [4,18]. Using data from a CMA performed in a
clinical genetics laboratory, Paciokowski et al. reported 11
CNVs in 11 patients referred for a clinical genetics evalu-
ation of IS [7]. Mefford et al. included 44 infantile spasms
cases in a large-scale CNV analysis for 315 children with
epileptic encephalopathy. Three pathogenic CNVs were
identified in 44 cases of IS (3/44=6.9%) [37]. These in-
clude a de novo deletion in CDKL5, an inherited duplica-
tion of 16p11.2, and an inherited deletion of 12q12. In the
last study, Tiwari et al. identified 4 known CNVs in 11 IS
cases. These include a de novo duplication of maternal ori-
gin in the 15q11-q13 region, a deletion of Xp22.13 con-
taining CDKL5, a deletion of 16p11.2 and an inherited
deletion of 2q32.2 [8]. Although the sample size was still
small, our study provides further evidence from a different
population supporting the role of CNVs in the etiology of
IS. More importantly, the identification of CNVs in 1q44
and deletion of 2q23.1 indicate that HNRNPU and MBD5
genes play significant roles contributing to the susceptibil-
ity of IS.
MBD5 belongs to the methyl-CpG DNA binding pro-
tein family that includes MeCP2, a gene that causes Rett
syndrome [44]. MBD5 is highly expressed in the brain
but its function in brain remains uncharacterized [45].
Mice with null mutations in Mbd5 displayed growth re-
tardation, small brain size, and early postnatal lethality
[45]. These results indicate that Mbd5 is important for
brain development but the exact role of Mbd5 remains
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MBD5 in humans, an interesting question for investiga-
tion is whether the Mbd5 heterozygous mutant mice re-
capitulate the clinical features observed in humans,
including IS. HNRNPU belongs to the family of hetero-
geneous nuclear ribonucleoproteins (hnRNPs) proteins
that associate with nascent RNA polymerase II tran-
s c r i p t st of o r mh n R N Pc o m p l e x e s[ 4 6 ] .HNRNPU is
thought to influence the structure of hnRNA and to
participate in pre-mRNA processing but the function of
HNRNPU in the brain has not been studied.
Generalized seizures have been recognized as one of
the common comorbidities in ASD [47]. The clinical as-
sociation between ASD and IS is also well recognized
[2]. However, the exact molecular link between ASD and
seizure remains poorly understood. The topic as to
whether seizure or autism is the primary pathophysi-
ology is a subject for ongoing debate. In cases with both
IS and ASD, chronologically, the infantile spasms usually
present before the signs and symptoms of autistic fea-
tures emerge, thus the pathophysiology of IS may be the
primary mechanism for ASD. However, it is equally pos-
sible that different pathophysiology at different develop-
mental stages is responsible for IS and ASD. Together
with other genes such as TSC1/2 and CDKL5, the impli-
cation of MBD5, a strong ASD causative gene, in IS
supports the molecular link between ASD and IS. Our
findings certainly support a medical re-sequencing study
of MBD5 in a large number of children with IS to con-
solidate the role of MBD5 in IS, and provide an oppor-
tunity to further dissect the molecular link between the
IS and ASD.
Conclusions
We reported the first genome wide copy number variation
analysis in Chinese children with IS. Our findings of the
CNVs of 1q21.1 gain and 1q44, 2q31.1, 17p13.3 loss in
Chinese IS children not only support the pathogenic
CNVs are conserved across different ethnic backgrounds,
but also specifically implicate the MBD5 and HNRNPU
genes in IS. The finding of MBD5 in both ASD and IS also
offers the opportunity to dissect the shared molecular
pathophysiology between ASD and infantile spasms.
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Table 3 Comparison between this study and published CNV and WES studies of infantile spasms
CNV studies WES (epi4K)
4,18
No of case This study Mefford, et al [37] Tiwari, et al [8] Paciokowski, et al [7] Epi4K Consortium & Epilepsy
Phenome/Genome Project
47 44 13 N/A (clinical case series
from diagnostic lab)
infantile spasms ( n=149)
Lennox–Gastaut syndrome
(n= 115).
Pathogenic/Possible
pathogenic CNV
43 4 1 1 329 de novo mutation
De novo: De novo: De novo: De novo: Mutations in more than one
proband
17p13 115 kb del Xp22 290 kb del 15q11 4.8 Mb dup 2p16.1 4.0 Mb del SCN1A; STXBP1; GABRB3;
1q44 2.1 Mb del 16p11. 2.5 Mb dup 16p11.2 595 kb del
a 3p26.3 1.6 Mb dup CDKL5; SCN8A; SCN2A;
2q23.1 4.1 Mb del 3q11 1.64 Mb dup Xp22.11 del
a,b 7q11.23 1.4 Mb del ALG13; DNM1; HDAC4
1q21 2.1 Mb dup 14q12 3.3 Mb dup
Inherited: 14q32.3 317 kb dup Other candidate genes:
2q32.3 421 kb del 15q11-q13 5.3 Mb dup CACN1A; CHD2; FLNA;
19q12 1.3 Mb del GABRB1; GRIN1; GRIN2B;
20p13 1.9 Mb del HNRNPU; IQSEC2; MTOR;
21q21 1.3 Mb dup NEDD4L
21q21 1.3 Mb dup
Xp22.2 435 kb dup
Unknown
2q24.3 21.5 Mb dup
aThe two CNV observed in one proband.
bSize is unknown.
del, deletion; dup, duplication.
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